United Immunity is a research firm that specializes in development, and supply of pharmaceuticals, mainly for cancer immunotherapy.
United Immunity has raised $1.2M in total funding. The most recent round was Debt Financing. The last funding was announced in March 2024.
United Immunity's investors include Mitsubishi UFJ Capital, UTEC - The University of Tokyo Edge Capital Partners, Aozora Corporate Investment, Saisei Ventures, Axil Capital.
United Immunity is headquartered in Tokyo, Japan.
United Immunity is a research firm that specializes in development, and supply of pharmaceuticals, mainly for cancer immunotherapy.
United Immunity is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"United Immunity — Funding & Investors." VCBacked, March 18, 2024, https://www.vcbacked.co/company/united-immunity. Accessed August 14, 2026.
VCBacked. (2024). United Immunity — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/united-immunity
{{cite web |title=United Immunity — Funding & Investors |url=https://www.vcbacked.co/company/united-immunity |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated